A small Canadian company has waded into a U.S. drug price controversy by offering to make an expensive prostate cancer drug for a fraction of the price.

Right now Xtandi costs U.S. patients as much as $129,000 US a year, or about $90 per pill. St. Catharines, Ont.-based Biolyse Pharma says it can make the drug for $3 a pill, or $4,400 per year, but has so far been unable to get U.S. health authorities to override the existing patent.

Read the article here.

Leave a Comment

Scroll to Top